Cambridge Cognition, a provider of cognitive assessment software for clinical trials, has announced its second commercial partnership with a pharmaceutical company, for its NeuroVocalix platform.
NeuroVocalix is a voice biomarker technology which was launched last year. It enables voice-based cognitive assessments to be delivered directly to patients via mobile and tele-health platforms, helping to improve outcomes in clinical trials.
Go deeper with GlobalData
The novel platform also aids in clinical decision-making and plays a key role in the management of long-term conditions such as chronic pain.
Cambridge Cognition CEO Matthew Stork said: “We are delighted to have received an order from a leading pharmaceutical company to trial the NeuroVocalix platform.
“Providing automated verbal testing and at the same time identifying voice biomarkers during clinical trials could help accelerate and improve the quality of clinical trials, benefiting patients across the world and providing a major opportunity for Cambridge Cognition.”
Verbal neuropsychological tests are used in cognitive research and clinical trials. However, employing them in home based monitoring programmes has been limited by a dependence on skilled raters. NeuroVocalix platform, which automatically administers voice based cognitive assessments, was developed to address this need.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalDataThe platform will be used to deliver remote assessments and to conduct clinical trials at a stretch effective without the need of skilled raters to supervise every visit.
According to the company, the platform supports exploration into potential voice based biomarkers, such as objectively quantifying the mental effort participants have to use to complete the task.
Cambridge Cognition said in a statement: “Cambridge Cognition will deploy the software directly onto participants’ own smartphones; supporting them to engage in the testing protocol from the comfort of their own homes.”
Last March, the company secured a grant from Innovate UK, which provided financing towards the development of the platform.
The NeuroVocalix platform is intended to be particularly useful for patients suffering with Alzheimer’s disease.
